General
Preferred name
(+)-TBZ
Synonyms
(+)-Tetrabenazine D6 ()
Tetrabenazine D6 ()
Ro 1-9569 D6 ()
(3R,11bR)-Tetrabenazine ()
(3R,11bR)-TBZ ()
Ro 1-9569 ()
deutetrabenazine ()
(+)-Tetrabenazine ()
Tetrabenazine-d6 ()
P&D ID
PD012124
CAS
1392826-25-3
1026016-83-0
Tags
available
drug
Drug indication
Huntington disease
Tardive dyskinesia
Drug Status
approved
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
(+)-Tetrabenazine ((+)-TBZ; (3R,11bR)-TBZ; (3R,11bR)-Tetrabenazine) is a reversible inhibitor of vesicular monoamine transporter 2 (VMAT-2), inhibits transport by VMAT2 with 10-fold greater potency than transport by VMAT1. ;target: VMAT-2;In vitro: (+)-Tetrabenazine inhibit the activity of the transporter but appear to interact differently with the protein. [2] (+)-Tetrabenazine inhibits reserpine binding to the transporter, suggesting that the sites may interact in an allosteric manner. [1];In vivo: 0.9% saline (80%) and dimethylsulfoxide (DMSO) (20%). (+)-Tetrabenazine blocks dopamine (DA) storage and depletes striatal DA; (+)-Tetrabenazine was shown to induce tremulous jaw movements (TJMs) in rats and mice. The reference dose for administration is 2.0 mg/kg.[2]
PRICE
33
DESCRIPTION
This is an orally available, deuterated analogue of which can be administered in lower doses and in a simplified dosing regimen.
In drug discovery, replacing hydrogen atoms in drug compounds with deuterium (deuteration) is a technique employed to inhibit degradation of the drug and its active metabolites. The presence of the deuterium atoms attenuates CYP2D6-driven metabolic breakdown of the compound. This effects an increase in circulating half-lives and improves the duration of therapeutic effect and decreases the dose required to achieve therapeutic concentration .
In drug discovery, replacing hydrogen atoms in drug compounds with deuterium (deuteration) is a technique employed to inhibit degradation of the drug and its active metabolites. The presence of the deuterium atoms attenuates CYP2D6-driven metabolic breakdown of the compound. This effects an increase in circulating half-lives and improves the duration of therapeutic effect and decreases the dose required to achieve therapeutic concentration .
DESCRIPTION
This is an orally available, deuterated analogue of which can be administered in lower doses and in a simplified dosing regimen. Deutetrabenazine is the first ever deuterated drug to be approved.
In drug discovery, replacing hydrogen atoms in drug compounds with deuterium (deuteration) is a technique employed to inhibit degradation of the drug and its active metabolites. The presence of the deuterium atoms attenuates CYP2D6-driven metabolic breakdown of the compound. This effects an increase in circulating half-lives and improves the duration of therapeutic effect and decreases the dose required to achieve therapeutic concentration . (GtoPdb)
In drug discovery, replacing hydrogen atoms in drug compounds with deuterium (deuteration) is a technique employed to inhibit degradation of the drug and its active metabolites. The presence of the deuterium atoms attenuates CYP2D6-driven metabolic breakdown of the compound. This effects an increase in circulating half-lives and improves the duration of therapeutic effect and decreases the dose required to achieve therapeutic concentration . (GtoPdb)
DESCRIPTION
(+)-Tetrabenazine ((3R,11bR)-Tetrabenazine) is a reversible vesicular monoamine transporter 2 (VMAT-2) inhibitor, inhibits transport by VMAT2 with 10-fold greater potency than transport by VMAT1.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
7
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
30
Molecular Weight
317.2
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
0
Rotatable Bonds
4
Ring Count
3
Aromatic Ring Count
1
cLogP
3.24
TPSA
38.77
Fraction CSP3
0.63
Chiral centers
2.0
Largest ring
6.0
QED
0.85
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Monoamine transporter
VMAT2
D2
Synaptic vesicular amine transporter
Pathway
Membrane Transporter/Ion Channel
GPCR/G protein
Neuroscience
MOA
dopamine receptor inhibitor
Others inhibitor
Source data
